Phase 3
Completed N=30
Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
Attention Deficit Disorder
Source: ClinicalTrials.gov NCT01883817 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcomePrimary: Attention-Deficit Hyperactivity Disorder Symptom Ratings Using the ADHD Rating Scale (ADHD-RS-IV) — 47.1; 46.1 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The study hypothesis is that DHA is more effective than placebo in increasing brain activation and reducing symptoms in psychostimulant-free children with ADHD.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Attention-Deficit Hyperactivity Disorder Symptom Ratings Using the ADHD Rating Scale (ADHD-RS-IV) |
47.1; 46.1 | — |
Eligibility Criteria
Inclusion Criteria
- Provision of written informed consent/assent
- Ages 5-15 years old
- Meets DSM-IV-TR criteria for ADHD as determined by the KSADS
Exclusion Criteria
- Contraindication to an MRI scan (i.e., braces, claustrophobia)
- A history of a major medical (e.g., diabetes) or neurological illness (e.g., epilepsy)
- Greater than 1 year outside appropriate age/grade level
- A history of intolerance or hypersensitivity to omega-3 fatty acids
- Currently taking omega-3 supplements
- Not proficient in English language
- Any history of a hematological disorder or concomitant use of anticoagulant medications
- Personal history of an Axis I psychiatric disorder other than ADHD
- Inability to swallow capsules
Data sourced from ClinicalTrials.gov (NCT01883817). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.